38596011|t|Serum cytokines profile changes in amyotrophic lateral sclerosis.
38596011|a|Background: Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder, characterized by progressive limb weakness, dysphagia, dysphonia, and respiratory failure due to degeneration of upper and lower motor neurons. The pathogenesis of ALS is still unclear. Neuroinflammation has been found to be involved in its development and progression. Cytokines play a significant role in the inflammatory process. This study aims to identify novel biomarkers that may assist in the diagnosis of ALS. Methods: In Fujian Medical University Union Hospital and Huashan Hospital Fudan University, two independent centers, we prospectively recruited 50 ALS patients, and 41 healthy controls (25 ALS and 26 controls in the first stage and 25 ALS and 15 controls in the validation stage). An 18-plex Luminex kit was used to screen the serum cytokines levels in the first stage. Commercial ELISA kits were used to measure the levels of target cytokines in the validation stage. A single-molecule array HD-X platform was applied to assess the levels of serum neurofilament light chain (NFL). Results: The levels of serum IL-18 were markedly increased in patients with ALS in the first stage (p = 0.016). The ROC curve showed an area under the curve at 0.695 (95% CI 0.50-0.84) in distinguishing ALS patients from healthy controls. The IL-21 was decreased in elderly patients when grouped by 55 years old (the medium age). Furthermore, the IL-5, IL-13, IL-18, and NFL had a positive relationship with the disease progression of ALS. We also found that serum IL-18 was markedly increased in ALS patients in the validation stage (167.67 [148.25-175.59] vs 116.44 [102.43-122.19]pg/ml, p < 0.0015). Conclusion: In this study, we identified systemic cytokine profile changes in the serum of ALS patients, especially the elevated IL-18, as well as the decreased IL-21 in elder patients. These changes in serum cytokine profiles may shed new light on an in-depth understanding of the immunopathogenic characteristics of ALS.
38596011	35	64	amyotrophic lateral sclerosis	Disease	MESH:D000690
38596011	78	107	Amyotrophic lateral sclerosis	Disease	MESH:D000690
38596011	109	112	ALS	Disease	MESH:D000690
38596011	131	157	neurodegenerative disorder	Disease	MESH:D019636
38596011	188	201	limb weakness	Disease	MESH:D018908
38596011	203	212	dysphagia	Disease	MESH:D003680
38596011	214	223	dysphonia	Disease	MESH:D055154
38596011	229	248	respiratory failure	Disease	MESH:D012131
38596011	323	326	ALS	Disease	MESH:D000690
38596011	345	362	Neuroinflammation	Disease	MESH:D000090862
38596011	470	482	inflammatory	Disease	MESH:D007249
38596011	573	576	ALS	Disease	MESH:D000690
38596011	725	728	ALS	Disease	MESH:D000690
38596011	729	737	patients	Species	9606
38596011	767	770	ALS	Disease	MESH:D000690
38596011	813	816	ALS	Disease	MESH:D000690
38596011	1127	1152	neurofilament light chain	Gene	4747
38596011	1154	1157	NFL	Gene	4747
38596011	1189	1194	IL-18	Gene	3606
38596011	1222	1230	patients	Species	9606
38596011	1236	1239	ALS	Disease	MESH:D000690
38596011	1363	1366	ALS	Disease	MESH:D000690
38596011	1367	1375	patients	Species	9606
38596011	1403	1408	IL-21	Gene	59067
38596011	1434	1442	patients	Species	9606
38596011	1507	1511	IL-5	Gene	3567
38596011	1513	1518	IL-13	Gene	3596
38596011	1520	1525	IL-18	Gene	3606
38596011	1531	1534	NFL	Gene	4747
38596011	1595	1598	ALS	Disease	MESH:D000690
38596011	1625	1630	IL-18	Gene	3606
38596011	1657	1660	ALS	Disease	MESH:D000690
38596011	1661	1669	patients	Species	9606
38596011	1854	1857	ALS	Disease	MESH:D000690
38596011	1858	1866	patients	Species	9606
38596011	1892	1897	IL-18	Gene	3606
38596011	1924	1929	IL-21	Gene	59067
38596011	1939	1947	patients	Species	9606
38596011	2081	2084	ALS	Disease	MESH:D000690
38596011	Association	MESH:D000690	4747
38596011	Association	MESH:D000690	3567
38596011	Positive_Correlation	MESH:D000690	3606
38596011	Association	MESH:D000690	3596

